China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Risk & Volatility
China SXT Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Profitability
This table compares China SXT Pharmaceuticals and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| China SXT Pharmaceuticals | N/A | N/A | N/A |
| Shionogi & Co., Ltd. Unsponsored ADR | 41.08% | 14.09% | 12.50% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| China SXT Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Shionogi & Co., Ltd. Unsponsored ADR | 1 | 1 | 0 | 0 | 1.50 |
Valuation and Earnings
This table compares China SXT Pharmaceuticals and Shionogi & Co., Ltd. Unsponsored ADR”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| China SXT Pharmaceuticals | $1.54 million | 1.05 | -$3.30 million | N/A | N/A |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 4.78 | $1.36 billion | $0.80 | 11.66 |
Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than China SXT Pharmaceuticals.
Insider and Institutional Ownership
5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Shionogi & Co., Ltd. Unsponsored ADR beats China SXT Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
